dehydroepiandrosterone has been researched along with Libman-Sacks Disease in 69 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dehydroepiandrosterone (DHEA) has been reported to improve fatigue and reduced well-being." | 9.14 | Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. ( Bijl, M; Bijlsma, JW; Derksen, RH; Geenen, R; Godaert, GL; Hartkamp, A, 2010) |
| "In patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), low levels of adrenal steroids have been repeatedly demonstrated, but the site of alteration has not been exactly described because measurements of serum pregnenolone and 17-hydroxypregnenolone (17OHPreg) together with other adrenal steroids have never been performed." | 7.72 | Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. ( Dorner, M; Falk, W; Schölmerich, J; Straub, RH; Vogl, D, 2003) |
| "Dehydroepiandrosterone (DHEA) has been reported to improve fatigue and reduced well-being." | 5.14 | Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. ( Bijl, M; Bijlsma, JW; Derksen, RH; Geenen, R; Godaert, GL; Hartkamp, A, 2010) |
| "In patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), low levels of adrenal steroids have been repeatedly demonstrated, but the site of alteration has not been exactly described because measurements of serum pregnenolone and 17-hydroxypregnenolone (17OHPreg) together with other adrenal steroids have never been performed." | 3.72 | Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. ( Dorner, M; Falk, W; Schölmerich, J; Straub, RH; Vogl, D, 2003) |
| " Fifteen non-CNS-SLE patients, 15 RA patients and 15 HC participants similar in age, education, and gender (female) were compared on tests of cognition, depression, and plasma levels of interleukin-6 (IL-6), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) and cortisol." | 3.71 | Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. ( Kozora, E; Laudenslager, M; Lemieux, A; West, SG, 2001) |
| "In adult women with active SLE, administration of prasterone at a dosage of 200 mg/day improved or stabilized signs and symptoms of disease and was generally well tolerated." | 2.71 | Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. ( Buyon, JP; Calabrese, LH; Caldwell, JR; Cohen, SB; Egan, RM; Fessler, BJ; Genovese, MC; Ginzler, EM; Gluck, OS; Goldman, AL; Greenwald, MW; Gurwith, M; Hobbs, K; Iannini, MJ; Kalunian, KC; Katz, RS; Kavanaugh, AF; Lahita, RG; Manzi, S; Mease, PJ; Merrill, JT; Moder, KG; Moreland, LW; Olsen, NJ; Petri, MA; Polisson, RP; Quarles, BJ; Ramsey-Goldman, R; Rothfield, NF; Schiff, MH; Schwartz, KE; Spencer, RT; St Clair, EW; Strand, V; Van Vollenhoven, R; Yocum, DE, 2004) |
| "To evaluate whether treatment with prasterone (dehydroepiandrosterone [DHEA]) would allow the dosage of prednisone (or an equivalent corticosteroid) to be reduced to < or = 7." | 2.70 | Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. ( Ginzler, EM; Gorelick, KJ; Kunz, A; Lahita, RG; Merrill, JT; Petri, MA; Schiff, M; Schwartz, KE; Strand, V; Van Vollenhoven, RF, 2002) |
| "To evaluate the efficacy and tolerability of dehydroepiandrosterone (DHEA) at a dosage of 200 mg/day in adult women with active systemic lupus erythematosus (SLE)." | 2.70 | Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. ( Chang, DM; Lan, JL; Lin, HY; Luo, SF, 2002) |
| "To examine in women with systemic lupus erythematosus (SLE) who participated in a clinical trial the relationship between daily dose of dehydroepiandrosterone (DHEA), serum levels of DHEA and DHEA sulfate (DHEAS), clinical effectiveness, and side effects." | 2.69 | Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response. ( Barry, NN; McGuire, JL; van Vollenhoven, RF, 1998) |
| "In the patients who were receiving DHEA, the SLEDAI score, patient's and physician's overall assessment of disease activity, and concurrent prednisone dosage decreased, while in the patients taking placebo, small increases were seen." | 2.68 | Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. ( Engleman, EG; McGuire, JL; van Vollenhoven, RF, 1995) |
| "Hydroxychloroquine is a crucial background medication in SLE with actions in many molecular pathways." | 2.53 | Immunomodulators in SLE: Clinical evidence and immunologic actions. ( Durcan, L; Petri, M, 2016) |
| "Dehydroepiandrosterone (DHEA) is a C19 steroid of adrenal origin." | 2.46 | Dehydroepiandrosterone as a regulator of immune cell function. ( Arlt, W; Hazeldine, J; Lord, JM, 2010) |
| "Dehydroepiandrosterone (DHEA) is a naturally occurring inactive steroid which may possess disease activity modifying properties as well as the ability to reduce flares and steroid requirements." | 2.44 | Dehydroepiandrosterone for systemic lupus erythematosus. ( Black, C; Crosbie, D; McIntyre, L; Royle, PL; Thomas, S, 2007) |
| "The pharmacology, pharmacokinetics, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration, and safety issues related to the use of prasterone are discussed." | 2.43 | Prasterone. ( Kocis, P, 2006) |
| "Systemic lupus erythematosus is a chronic autoimmune condition with a wide spectrum of clinical manifestations, characterized by the production of auto-antibodies to components of the cell nucleus." | 2.43 | Systemic lupus erythematosus: current state of diagnosis and treatment. ( Moldovan, I, 2006) |
| " In the US it received Orphan Drug designation, providing seven years of exclusive marketing rights, and in October 1996, Genelabs received US-05567696, covering the use of GL-701 in lupus patients to reduce their dosage of concomitant corticosteroids [222741], [329646]." | 2.41 | GL-701 Genelabs. ( Norman, P, 2001) |
| "Dehydroepiandrosterone (DHEA) is a steroid secreted by the adrenal cortex, with a characteristic, age-related, pattern of secretion." | 2.40 | DHEA deficiency syndrome: a new term for old age? ( Hinson, JP; Raven, PW, 1999) |
| "Dehydroepiandrosterone (DHEA) is a weak androgen that exerts pleomorphic effects on the immune system." | 1.35 | Dehydroepiandrosterone in systemic lupus erythematosus. ( Kovats, S; Sawalha, AH, 2008) |
| "In rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), patients demonstrate low levels of adrenal hormones." | 1.32 | Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. ( Demmel, B; Herrmann, M; Kees, F; Schedel, J; Schmidt, M; Schölmerich, J; Straub, RH; Weidler, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (11.59) | 18.7374 |
| 1990's | 15 (21.74) | 18.2507 |
| 2000's | 39 (56.52) | 29.6817 |
| 2010's | 7 (10.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Norman, P | 1 |
| Treadwell, EL | 1 |
| Wiley, K | 1 |
| Word, B | 2 |
| Melchior, W | 1 |
| Tolleson, WH | 1 |
| Gopee, N | 1 |
| Hammons, G | 1 |
| Lyn-Cook, BD | 2 |
| Durcan, L | 1 |
| Petri, M | 1 |
| Sánchez-Guerrero, J | 1 |
| Fragoso-Loyo, HE | 1 |
| Neuwelt, CM | 1 |
| Wallace, DJ | 1 |
| Ginzler, EM | 4 |
| Sherrer, YR | 1 |
| McIlwain, HH | 1 |
| Freeman, PG | 1 |
| Aranow, C | 1 |
| Petri, MA | 3 |
| Deodhar, AA | 1 |
| Blanton, E | 1 |
| Manzi, S | 2 |
| Kavanaugh, A | 1 |
| Lisse, JR | 1 |
| Ramsey-Goldman, R | 2 |
| McKay, JD | 1 |
| Kivitz, AJ | 1 |
| Mease, PJ | 3 |
| Winkler, AE | 1 |
| Kahl, LE | 1 |
| Lee, AH | 1 |
| Furie, RA | 1 |
| Strand, CV | 1 |
| Lou, L | 1 |
| Ahmed, M | 1 |
| Quarles, B | 1 |
| Schwartz, KE | 5 |
| Krysiak, R | 1 |
| Frysz-Naglak, D | 1 |
| Okopień, B | 1 |
| Sawalha, AH | 1 |
| Kovats, S | 1 |
| Hartkamp, A | 2 |
| Geenen, R | 2 |
| Godaert, GL | 2 |
| Bijl, M | 2 |
| Bijlsma, JW | 2 |
| Derksen, RH | 3 |
| Hazeldine, J | 1 |
| Arlt, W | 1 |
| Lord, JM | 1 |
| Marder, W | 1 |
| Somers, EC | 1 |
| Kaplan, MJ | 1 |
| Anderson, MR | 1 |
| Lewis, EE | 1 |
| McCune, WJ | 1 |
| Kahn, D | 1 |
| Wiley, KL | 1 |
| Treadwell, E | 1 |
| Manigaba, K | 1 |
| Lahita, RG | 4 |
| Van Vollenhoven, RF | 10 |
| Merrill, JT | 3 |
| Schiff, M | 2 |
| Strand, V | 2 |
| Kunz, A | 1 |
| Gorelick, KJ | 1 |
| Gescuk, BD | 1 |
| Davis, JC | 1 |
| Chang, DM | 2 |
| Lan, JL | 1 |
| Lin, HY | 1 |
| Luo, SF | 1 |
| Vogl, D | 1 |
| Falk, W | 1 |
| Dorner, M | 1 |
| Schölmerich, J | 4 |
| Straub, RH | 4 |
| Weidler, C | 1 |
| Demmel, B | 1 |
| Herrmann, M | 1 |
| Kees, F | 1 |
| Schmidt, M | 1 |
| Schedel, J | 1 |
| Iannini, MJ | 1 |
| Yocum, DE | 1 |
| Katz, RS | 1 |
| Gluck, OS | 2 |
| Genovese, MC | 2 |
| Van Vollenhoven, R | 1 |
| Kalunian, KC | 1 |
| Greenwald, MW | 1 |
| Buyon, JP | 2 |
| Olsen, NJ | 1 |
| Schiff, MH | 1 |
| Kavanaugh, AF | 1 |
| Caldwell, JR | 1 |
| St Clair, EW | 1 |
| Goldman, AL | 1 |
| Egan, RM | 1 |
| Polisson, RP | 1 |
| Moder, KG | 1 |
| Rothfield, NF | 1 |
| Spencer, RT | 1 |
| Hobbs, K | 1 |
| Fessler, BJ | 1 |
| Calabrese, LH | 1 |
| Moreland, LW | 1 |
| Cohen, SB | 1 |
| Quarles, BJ | 2 |
| Gurwith, M | 1 |
| Chu, SJ | 1 |
| Chen, HC | 1 |
| Kuo, SY | 1 |
| Lai, JH | 1 |
| Chen, CC | 1 |
| Parker, CR | 1 |
| Cameron, DR | 1 |
| Braunstein, GD | 1 |
| Meyer, P | 1 |
| Meier, CA | 1 |
| Goldman, A | 1 |
| Greenwald, M | 1 |
| Cohen, S | 1 |
| Egan, R | 1 |
| Alexander, T | 1 |
| Friel, PN | 1 |
| Wright, JV | 1 |
| Nordmark, G | 1 |
| Bengtsson, C | 1 |
| Larsson, A | 1 |
| Karlsson, FA | 1 |
| Sturfelt, G | 1 |
| Rönnblom, L | 1 |
| Kocis, P | 1 |
| Bácsi, K | 1 |
| Kósa, J | 1 |
| Lazáry, A | 1 |
| Horváth, H | 1 |
| Balla, B | 1 |
| Lakatos, P | 1 |
| Speer, G | 1 |
| Moldovan, I | 1 |
| Crosbie, D | 1 |
| Black, C | 1 |
| McIntyre, L | 1 |
| Royle, PL | 1 |
| Thomas, S | 1 |
| Miller, MH | 1 |
| Urowitz, MB | 1 |
| Gladman, DD | 1 |
| Killinger, DW | 1 |
| Dougados, M | 2 |
| Nahoul, K | 3 |
| Benhamou, L | 1 |
| Jungers, P | 3 |
| Laplane, D | 1 |
| Amor, B | 1 |
| Pélissier, C | 2 |
| Bach, JF | 2 |
| Tron, F | 1 |
| Suzuki, T | 2 |
| Suzuki, N | 2 |
| Engleman, EG | 4 |
| Mizushima, Y | 1 |
| Sakane, T | 3 |
| McGuire, JL | 6 |
| Zeuner, M | 1 |
| Antoniou, E | 1 |
| Lang, B | 1 |
| Morabito, LM | 1 |
| Barry, NN | 1 |
| Nippoldt, TB | 1 |
| Nair, KS | 1 |
| Park, JL | 1 |
| West, JP | 1 |
| Hinson, JP | 1 |
| Raven, PW | 1 |
| Zietz, B | 1 |
| Reber, T | 1 |
| Oertel, M | 1 |
| Glück, T | 1 |
| Furie, R | 1 |
| Bonney, RC | 1 |
| Kozora, E | 1 |
| Laudenslager, M | 1 |
| Lemieux, A | 1 |
| West, SG | 1 |
| Wallace, D | 1 |
| Patavino, T | 1 |
| Brady, DM | 1 |
| Liu, C | 1 |
| Zhou, H | 1 |
| Qu, R | 1 |
| Liu, Z | 1 |
| Abu-Shakra, M | 1 |
| Buskila, D | 1 |
| Mezalek, ZT | 1 |
| Tóth, E | 1 |
| Horváth, C | 1 |
| Vennemann, F | 1 |
| Tholen, S | 1 |
| Fehér, KG | 1 |
| Bencze, G | 1 |
| Ujfalussy, J | 1 |
| Fehér, T | 1 |
| Lucas, JA | 1 |
| Ahmed, SA | 1 |
| Casey, ML | 1 |
| MacDonald, PC | 1 |
| Iizuka, R | 1 |
| Yamanaka, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids[NCT00053560] | Phase 3 | 155 participants | Interventional | 2002-12-31 | Active, not recruiting | ||
| A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids[NCT00082511] | Phase 3 | 114 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration[NCT00391924] | Phase 2 | 120 participants | Interventional | 2000-05-31 | Completed | ||
| The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders[NCT02357472] | Phase 4 | 50 participants (Anticipated) | Interventional | 2014-12-31 | Active, not recruiting | ||
| Dehydroepiandrosterone (DHEA) Treatment for Sjogren's Syndrome[NCT00001598] | Phase 2 | 28 participants | Interventional | 1997-05-31 | Completed | ||
| Biological Effects of DHEA in the Elderly[NCT00111930] | 144 participants | Interventional | 2000-08-31 | Completed | |||
| Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Oral Contraceptives[NCT00000420] | Phase 3 | 350 participants | Interventional | 1997-06-30 | Completed | ||
| Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Hormone Replacement Therapy[NCT00000419] | Phase 3 | 350 participants | Interventional | 1996-04-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
31 reviews available for dehydroepiandrosterone and Libman-Sacks Disease
| Article | Year |
|---|---|
GL-701 Genelabs.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Pha | 2001 |
Immunomodulators in SLE: Clinical evidence and immunologic actions.
Topics: Adjuvants, Immunologic; B-Lymphocytes; Combined Modality Therapy; Dehydroepiandrosterone; Disease Ma | 2016 |
[Current views on the role of dehydroepiandrosterone in physiology, pathology and therapy].
Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenarche; Aged; Aging; Atherosclerosis; Cardiovascular Sys | 2008 |
Dehydroepiandrosterone as a regulator of immune cell function.
Topics: Aging; Animals; Dehydroepiandrosterone; Humans; Leukocytes; Lupus Erythematosus, Systemic; Lymphoid | 2010 |
Commentary on neuropsychiatric symptoms associated with lupus.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Affective Symptoms; Dehydroepiandrosterone; Diagnos | 2011 |
Novel therapeutic agents for systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; B-Lymphocytes; Biological Products; Dehydroepiandrosterone; Humans; Immune T | 2002 |
Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus.
Topics: Androgens; Animals; Dehydroepiandrosterone; Drugs, Investigational; Gonadal Steroid Hormones; Humans | 2003 |
Adrenal androgens and the immune system.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Glands; Androgens; Animals; Arthritis, Rheumatoid; Criti | 2004 |
The use of dehydroepiandrosterone therapy in clinical practice.
Topics: Adrenal Insufficiency; Aging; Alzheimer Disease; Bone Density; Cardiovascular Diseases; Dehydroepian | 2005 |
[Focus on dehydroepiandrosterone (DHEA)].
Topics: Adrenal Insufficiency; Aging; Body Composition; Dehydroepiandrosterone; Humans; Lupus Erythematosus, | 2005 |
Prasterone.
Topics: Adjuvants, Immunologic; Adult; Biological Availability; Bone Density; Dehydroepiandrosterone; Drug A | 2006 |
[Significance of dehydroepiandrosterone and dehydroepiandrosterone sulfate in different diseases].
Topics: Androgens; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Diabetes | 2007 |
Systemic lupus erythematosus: current state of diagnosis and treatment.
Topics: Adjuvants, Immunologic; Dehydroepiandrosterone; Hematopoietic Stem Cell Transplantation; Humans; Imm | 2006 |
Dehydroepiandrosterone for systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Dehydroepiandrosterone; Humans; Lupus Erythematosus, Systemic; Randomized Co | 2007 |
Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus.
Topics: Animals; Dehydroepiandrosterone; Humans; Interleukin-2; Lupus Erythematosus, Systemic; Mice; T-Lymph | 1996 |
Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.
Topics: Dehydroepiandrosterone; Humans; Lupus Erythematosus, Systemic | 1996 |
Dehydroepiandrosterone (DHEA) and lupus erythematosus: an update.
Topics: Dehydroepiandrosterone; Humans; Lupus Erythematosus, Systemic | 1997 |
Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus.
Topics: Aged; Aged, 80 and over; Animals; Clinical Trials as Topic; Dehydroepiandrosterone; Drug Administrat | 1998 |
Is there a case for DHEA replacement?
Topics: Adult; Aged; Aging; Alzheimer Disease; Animals; Arteriosclerosis; Bone Remodeling; Carbohydrate Meta | 1998 |
Dehydroepiandrosterone (DHEA) for serious disease, a possibility?
Topics: Dehydroepiandrosterone; Humans; Lupus Erythematosus, Systemic; Randomized Controlled Trials as Topic | 1999 |
DHEA deficiency syndrome: a new term for old age?
Topics: Adolescent; Adrenal Cortex; Adult; Aged; Aged, 80 and over; Aging; Child; Cognition Disorders; Dehyd | 1999 |
Dehydroepiandrosterone in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Animals; Clinical Trials as Topic; Dehydroepiandrosterone; Disease Models, A | 2000 |
Clinical trials in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Clinical Trials, Phase III as Topic; Dehydroepiandrosterone; Female; Humans; | 2000 |
Clinical trials in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Clinical Trials, Phase III as Topic; Dehydroepiandrosterone; Female; Humans; | 2000 |
Clinical trials in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Clinical Trials, Phase III as Topic; Dehydroepiandrosterone; Female; Humans; | 2000 |
Clinical trials in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Clinical Trials, Phase III as Topic; Dehydroepiandrosterone; Female; Humans; | 2000 |
Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Biological Products; Clinical Trials as Topic; Dehydroepiandrosterone; Femal | 2000 |
Systemic lupus erythematosus.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Dehydroepiandrosterone; Drugs, Investigational; Fe | 2001 |
Current and emerging lupus treatments.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Dehydroepiandroster | 2001 |
Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Age Factors; Animals; Antioxidants; Complementary Therapies; Dehydroepiandro | 2001 |
Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.
Topics: Acne Vulgaris; Adjuvants, Immunologic; Animals; Clinical Trials as Topic; Cognition; Dehydroepiandro | 2002 |
Autoimmunity, dehydroepiandrosterone (DHEA), and stress.
Topics: Adjuvants, Immunologic; Apoptosis; Arthritis, Rheumatoid; Cytokines; Dehydroepiandrosterone; Humans; | 2002 |
[The role of adrenal and gonadal hormones in the pathogenesis of autoimmune polyarthritis].
Topics: Androgens; Arthritis; Arthritis, Rheumatoid; Autoantigens; Chronic Disease; Dehydroepiandrosterone; | 2002 |
[SLE and pregnancy--effect of exogenous corticosteroids on urinary excretion of estriol].
Topics: Adult; Corticosterone; Dehydroepiandrosterone; Estriol; Female; Humans; Lupus Erythematosus, Systemi | 1973 |
17 trials available for dehydroepiandrosterone and Libman-Sacks Disease
| Article | Year |
|---|---|
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Dehydroepiandrosterone; Dose-Response Relatio | 2008 |
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Topics: Adult; Aged; Dehydroepiandrosterone; Depression; Double-Blind Method; Fatigue; Female; Follow-Up Stu | 2010 |
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Topics: Adult; Aged; Dehydroepiandrosterone; Depression; Double-Blind Method; Fatigue; Female; Follow-Up Stu | 2010 |
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Topics: Adult; Aged; Dehydroepiandrosterone; Depression; Double-Blind Method; Fatigue; Female; Follow-Up Stu | 2010 |
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Topics: Adult; Aged; Dehydroepiandrosterone; Depression; Double-Blind Method; Fatigue; Female; Follow-Up Stu | 2010 |
Effects of prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study.
Topics: Adjuvants, Immunologic; Adult; Atherosclerosis; Bone Density; Cholesterol, HDL; Cross-Over Studies; | 2010 |
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Dehydroepiandrosterone; Double-Bli | 2002 |
Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Adult; Dehydroepiandrosterone; Double-Blind Method; Female; Humans; Lupus Erythematosus, Systemic | 2002 |
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Adult; Dehydroepiandrosterone; Double-Blind Method; Female; Humans; Lupus Er | 2004 |
The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Bone Density; Dehydroepiandrosterone; Diphospho | 2004 |
Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.
Topics: Adolescent; Adult; Antirheumatic Agents; Dehydroepiandrosterone; Double-Blind Method; Estradiol; Fem | 2004 |
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Topics: Adjuvants, Immunologic; Adult; Bone Density; Dehydroepiandrosterone; Double-Blind Method; Female; Gl | 2005 |
Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Adrenocorticotropic Hormone; Adult; Aged; Androgens; Dehydroepiandrosterone; | 2005 |
An open study of dehydroepiandrosterone in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Aged; Androgens; Dehydroepiandrosterone; Female; Humans; Lupus Eryth | 1994 |
Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus.
Topics: Adult; Cell Adhesion Molecules; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; E-Selectin; | 1996 |
Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
Topics: Adult; Chi-Square Distribution; Dehydroepiandrosterone; Double-Blind Method; Drug Therapy, Combinati | 1995 |
Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Feasibility Studies; Female; Humans; | 1998 |
Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
Topics: Acne Vulgaris; Adjuvants, Immunologic; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dose- | 1998 |
A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Bone Density; Dehydroepiandrosterone; Double-Blind Method; Drug Ther | 1999 |
Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor.
Topics: Adrenocorticotropic Hormone; Androstenedione; Corticotropin-Releasing Hormone; Dehydroepiandrosteron | 2000 |
21 other studies available for dehydroepiandrosterone and Libman-Sacks Disease
| Article | Year |
|---|---|
Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/T.
Topics: Adult; Black or African American; Dehydroepiandrosterone; Female; Gene Expression; Gene Frequency; G | 2015 |
Dehydroepiandrosterone in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Adult; Animals; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; F | 2008 |
Ethnic differences in DNA methyltransferases expression in patients with systemic lupus erythematosus.
Topics: Black or African American; Dehydroepiandrosterone; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytos | 2013 |
Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones.
Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; Adrenal Cortex; Adult; Aged; Androstened | 2003 |
Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Cortex Hormones; Adult; Androstenedione; Arthritis, Rheumatoid | 2004 |
Dehydroepiandrosterone (DHEA).
Topics: Adjuvants, Immunologic; Adolescent; Adrenal Insufficiency; Adult; Aging; Alzheimer Disease; Dehydroe | 2005 |
Prasterone and bone mineral density in women with systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Bone Density; Dehydroepiandrosterone; Female; Humans; Lupus Erythematosus, S | 2005 |
Systemic lupus erythematosus in males.
Topics: Adult; Aged; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Estrone; Female; HLA | 1983 |
[Study of plasma androgens in women with autoimmune diseases].
Topics: Adolescent; Adult; Androgens; Androstenedione; Arthritis, Rheumatoid; Autoimmune Diseases; Dehydroep | 1984 |
[Plasma androgens in women with systemic lupus erythematosus].
Topics: Adolescent; Adult; Androgens; Androstenedione; Dehydroepiandrosterone; Dihydrotestosterone; Female; | 1980 |
Low plasma androgens in women with active or quiescent systemic lupus erythematosus.
Topics: Adolescent; Adult; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestost | 1982 |
Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE).
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dehydroepiandrosterone; Female; Human | 1995 |
Dehydroepiandrosterone in the treatment of systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Dehydroepiandrosterone; Humans; Lupus Erythematosus, Systemic | 2000 |
Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Attention; Case-Control Studies; Cognition; | 2001 |
Effects of sex hormones on apoptosis in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Topics: Adult; Apoptosis; Dehydroepiandrosterone; DNA; Estradiol; Female; Gonadal Steroid Hormones; Humans; | 2001 |
Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference.
Topics: Antimalarials; Biological Therapy; Congresses as Topic; Cyclophosphamide; Dehydroepiandrosterone; He | 2002 |
[Systemic lupus erythematosus. International Conference on Systemic Lupus Erythematosus, Barcelona, March 24-28, 2001].
Topics: Adjuvants, Immunologic; Age Factors; Antimalarials; Antiphospholipid Syndrome; Cyclophosphamide; Deh | 2002 |
[Physiopathology of systemic lupus erythematosus].
Topics: Amino Acid Sequence; Antibodies, Antinuclear; B-Lymphocytes; Dehydroepiandrosterone; DNA; Humans; In | 1992 |
[Sex hormones in lupus erythematosus].
Topics: Adult; Aged; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone; Gonadal Steroi | 1986 |
Serum steroid hormone levels in systemic lupus erythematosus (SLE).
Topics: Adolescent; Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; Gonada | 1987 |
Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone.
Topics: Animals; Antibodies, Antinuclear; Antibody Formation; Autoantibodies; Dehydroepiandrosterone; DNA; L | 1985 |